CRISPR technique

May 14, 2024

Takeda and AC Immune’s Alzheimer’s Deal; Eli Lilly’s Donanemab FDA Review; Bristol Myers Squibb’s Phase III CheckMate -73L Trial Result; Regeneron Pharmaceuticals’ Dupixent sBLA; Excision BioTherapeutics’ EBT-101 Phase I/II Trial Results

Dec 15, 2023

Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Jun 10, 2022

Unraveling the Potential of CRISPR Technology in the Gene-editing Space

Jan 02, 2018

NOTIZIA

Newsletter/Whitepaper